This drug is under clinical trials in phase I for humans—“Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation” [40]. This evidence concerns the gene PALB2 and hypoparathyroidism-retardation-dysmorphism syndrome.